OBJECTIVES: Pancreatic cancer has a 5-year survival rate of less than 5%, partly because of limited chemotherapeutic options, thereby highlighting the need for novel therapies. Triptolide, a diterpene triepoxide that was derived from a Chinese herb, has shown great promise in preclinical testing against pancreatic cancer using immunocompromised animals. RESULTS: In this study, we tested the ability of triptolide to induce cell death in cell lines derived from a primary tumor and adjacent liver metastases of immunocompetent animals (Kras, Trp53, Pdx-1 Cre [KPC]). Both cell lines were more aggressive in their ability to form tumors when compared with other pancreatic cancer cell lines and showed constitutive activation of the nuclear factor κ-light-chain-enhancer of activated B cells pathway. Triptolide induced apoptotic cell death in both cell lines, as evidenced by decreased cell viability as well as increased caspase 3/7 activity, annexin V positivity, and increased terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling positivity in tumors from KPC animals treated with Minnelide. In addition, triptolide decreased levels of HSP70, its transcription factor HSF1, as well as the antiapoptotic proteins Bcl-xL, Bcl-2, and Mcl-1, which are known to be up-regulated in pancreatic cancer. CONCLUSIONS: The ability of triptolide to cause cell death in cell lines derived from immunocompetent animals further validates its potential as a novel agent against pancreatic cancer.
OBJECTIVES:Pancreatic cancer has a 5-year survival rate of less than 5%, partly because of limited chemotherapeutic options, thereby highlighting the need for novel therapies. Triptolide, a diterpene triepoxide that was derived from a Chinese herb, has shown great promise in preclinical testing against pancreatic cancer using immunocompromised animals. RESULTS: In this study, we tested the ability of triptolide to induce cell death in cell lines derived from a primary tumor and adjacent liver metastases of immunocompetent animals (Kras, Trp53, Pdx-1 Cre [KPC]). Both cell lines were more aggressive in their ability to form tumors when compared with other pancreatic cancer cell lines and showed constitutive activation of the nuclear factor κ-light-chain-enhancer of activated B cells pathway. Triptolide induced apoptotic cell death in both cell lines, as evidenced by decreased cell viability as well as increased caspase 3/7 activity, annexin V positivity, and increased terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling positivity in tumors from KPC animals treated with Minnelide. In addition, triptolide decreased levels of HSP70, its transcription factor HSF1, as well as the antiapoptotic proteins Bcl-xL, Bcl-2, and Mcl-1, which are known to be up-regulated in pancreatic cancer. CONCLUSIONS: The ability of triptolide to cause cell death in cell lines derived from immunocompetent animals further validates its potential as a novel agent against pancreatic cancer.
Authors: Yi Xia; Yang Liu; Palma Rocchi; Menghua Wang; Yuting Fan; Fanqi Qu; Juan L Iovanna; Ling Peng Journal: Cancer Lett Date: 2012-01-20 Impact factor: 8.679
Authors: Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani Journal: Cancer Cell Date: 2012-03-20 Impact factor: 31.743
Authors: Kimberly A Clawson; Daniel Borja-Cacho; Mara B Antonoff; Ashok K Saluja; Selwyn M Vickers Journal: J Surg Res Date: 2010-04-25 Impact factor: 2.192
Authors: Michael A Jacobetz; Derek S Chan; Albrecht Neesse; Tashinga E Bapiro; Natalie Cook; Kristopher K Frese; Christine Feig; Tomoaki Nakagawa; Meredith E Caldwell; Heather I Zecchini; Martijn P Lolkema; Ping Jiang; Anne Kultti; Curtis B Thompson; Daniel C Maneval; Duncan I Jodrell; Gregory I Frost; H M Shepard; Jeremy N Skepper; David A Tuveson Journal: Gut Date: 2012-03-30 Impact factor: 23.059
Authors: Seung Tae Kim; Sun Young Kim; Jeeyun Lee; Kyung Kim; Se Hoon Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Joon Oh Park Journal: BMC Cancer Date: 2018-11-12 Impact factor: 4.430